These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 35113160)

  • 1. Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue.
    Fernandez AI; Liu M; Bellizzi A; Brock J; Fadare O; Hanley K; Harigopal M; Jorns JM; Kuba MG; Ly A; Podoll M; Rabe K; Sanders MA; Singh K; Snir OL; Soong TR; Wei S; Wen H; Wong S; Yoon E; Pusztai L; Reisenbichler E; Rimm DL
    JAMA Oncol; 2022 Apr; 8(4):1-4. PubMed ID: 35113160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-institutional Assessment of Pathologist Scoring HER2 Immunohistochemistry.
    Robbins CJ; Fernandez AI; Han G; Wong S; Harigopal M; Podoll M; Singh K; Ly A; Kuba MG; Wen H; Sanders MA; Brock J; Wei S; Fadare O; Hanley K; Jorns J; Snir OL; Yoon E; Rabe K; Soong TR; Reisenbichler ES; Rimm DL
    Mod Pathol; 2023 Jan; 36(1):100032. PubMed ID: 36788069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Laboratory compliance with the American Society of Clinical Oncology/college of American Pathologists guidelines for human epidermal growth factor receptor 2 testing: a College of American Pathologists survey of 757 laboratories.
    Nakhleh RE; Grimm EE; Idowu MO; Souers RJ; Fitzgibbons PL
    Arch Pathol Lab Med; 2010 May; 134(5):728-34. PubMed ID: 20441503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform.
    Wu NC; Wong W; Ho KE; Chu VC; Rizo A; Davenport S; Kelly D; Makar R; Jassem J; Duchnowska R; Biernat W; Radecka B; Fujita T; Klein JL; Stonecypher M; Ohta S; Juhl H; Weidler JM; Bates M; Press MF
    Breast Cancer Res Treat; 2018 Nov; 172(2):327-338. PubMed ID: 30120700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detailed Reanalysis of 500 Breast Cancers With Equivocal HER2 Immunohistochemistry and Borderline ERBB2 Fluorescence In Situ Hybridization Results.
    Geiersbach KB; Sill DR; Del Rosario KM; Meyer RG; Spears GM; Yuhas JA; Sukov WR; Jenkins RB; Ocal IT; Mounajjed T; Chen B
    Am J Clin Pathol; 2021 Oct; 156(5):886-894. PubMed ID: 33942843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interlaboratory comparison of immunohistochemical testing for HER2: results of the 2004 and 2005 College of American Pathologists HER2 Immunohistochemistry Tissue Microarray Survey.
    Fitzgibbons PL; Murphy DA; Dorfman DM; Roche PC; Tubbs RR;
    Arch Pathol Lab Med; 2006 Oct; 130(10):1440-5. PubMed ID: 17090184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.
    Tafe LJ; Janjigian YY; Zaidinski M; Hedvat CV; Hameed MR; Tang LH; Hicks JB; Shah MA; Barbashina V
    Arch Pathol Lab Med; 2011 Nov; 135(11):1460-5. PubMed ID: 22032573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Limited human epidermal growth factor receptor 2 discordance in metastatic breast cancer patients treated with trastuzumab, a population based study.
    van Rooijen JM; de Munck L; de Graaf JC; Siesling S; de Vries EG; Boers JE
    Eur J Cancer; 2014 Mar; 50(5):885-91. PubMed ID: 24491395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Next-generation assessment of human epidermal growth factor receptor 2 gene (ERBB2) amplification status in invasive breast carcinoma: a focus on Group 4 by use of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 testing guideline.
    Hoda RS; Bowman AS; Zehir A; Razavi P; Brogi E; Ladanyi M; Arcila ME; Wen HY; Ross DS
    Histopathology; 2021 Mar; 78(4):498-507. PubMed ID: 32841416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Laboratory compliance with the American Society of Clinical Oncology/College of American Pathologists human epidermal growth factor receptor 2 testing guidelines: a 3-year comparison of validation procedures.
    Dyhdalo KS; Fitzgibbons PL; Goldsmith JD; Souers RJ; Nakhleh RE
    Arch Pathol Lab Med; 2014 Jul; 138(7):876-84. PubMed ID: 24978913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.
    Bastien RR; Rodríguez-Lescure Á; Ebbert MT; Prat A; Munárriz B; Rowe L; Miller P; Ruiz-Borrego M; Anderson D; Lyons B; Álvarez I; Dowell T; Wall D; Seguí MÁ; Barley L; Boucher KM; Alba E; Pappas L; Davis CA; Aranda I; Fauron C; Stijleman IJ; Palacios J; Antón A; Carrasco E; Caballero R; Ellis MJ; Nielsen TO; Perou CM; Astill M; Bernard PS; Martín M
    BMC Med Genomics; 2012 Oct; 5():44. PubMed ID: 23035882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concordance of HER2-low scoring in breast carcinoma among expert pathologists in the United Kingdom and the republic of Ireland -on behalf of the UK national coordinating committee for breast pathology.
    Zaakouk M; Quinn C; Provenzano E; Boyd C; Callagy G; Elsheikh S; Flint J; Millican-Slater R; Gunavardhan A; Mir Y; Makhija P; Di Palma S; Pritchard S; Tanchel B; Rakha E; Atallah NM; Lee AHS; Pinder S; Shaaban AM
    Breast; 2023 Aug; 70():82-91. PubMed ID: 37419078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer.
    Bouchalová K; Trojanec R; Kolár Z; Cwiertka K; Cernáková I; Mihál V; Hajdúch M
    Neoplasma; 2006; 53(5):393-401. PubMed ID: 17013533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of HER2 status in breast cancer: overall positivity rate and accuracy by fluorescence in situ hybridization and immunohistochemistry in a single institution over 12 years: a quality control study.
    Varga Z; Noske A; Ramach C; Padberg B; Moch H
    BMC Cancer; 2013 Dec; 13():615. PubMed ID: 24377754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and Validation of a HER2-Low Focused Immunohistochemical Scoring System With High-Interobserver Concordance: The Australian HER2-Low Breast Cancer Concordance Study.
    Farshid G; Armes J; Dessauvagie B; Gilhotra A; Kumar B; Mahajan H; Millar E; Pathmanathan N; Snell C
    Mod Pathol; 2024 Aug; 37(8):100535. PubMed ID: 38852812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concordance between central and local laboratory HER2 testing from a community-based clinical study.
    Reddy JC; Reimann JD; Anderson SM; Klein PM
    Clin Breast Cancer; 2006 Jun; 7(2):153-7. PubMed ID: 16800975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma.
    Couturier J; Vincent-Salomon A; Nicolas A; Beuzeboc P; Mouret E; Zafrani B; Sastre-Garau X
    Mod Pathol; 2000 Nov; 13(11):1238-43. PubMed ID: 11106082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PGDS, a novel technique combining chromogenic in situ hybridization and immunohistochemistry for the assessment of ErbB2 (HER2/neu) status in breast cancer.
    Ni R; Mulligan AM; Have C; O'Malley FP
    Appl Immunohistochem Mol Morphol; 2007 Sep; 15(3):316-24. PubMed ID: 17721278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimating copy number using next-generation sequencing to determine ERBB2 amplification status.
    Nakamura K; Aimono E; Oba J; Hayashi H; Tanishima S; Hayashida T; Chiyoda T; Kosaka T; Hishida T; Kawakubo H; Kitago M; Okabayashi K; Funakoshi T; Okita H; Ikeda S; Takaishi H; Nishihara H
    Med Oncol; 2021 Mar; 38(4):36. PubMed ID: 33710417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reading immunohistochemical slides on a computer monitor--a multisite performance study using 180 HER2-stained breast carcinomas.
    Nassar A; Cohen C; Albitar M; Agersborg SS; Zhou W; Lynch KA; Heyman ER; Lange H; Siddiqui MT
    Appl Immunohistochem Mol Morphol; 2011 May; 19(3):212-7. PubMed ID: 21475038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.